MX2023000784A - Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). - Google Patents

Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).

Info

Publication number
MX2023000784A
MX2023000784A MX2023000784A MX2023000784A MX2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A MX 2023000784 A MX2023000784 A MX 2023000784A
Authority
MX
Mexico
Prior art keywords
muc1
ecd
extracellular domain
antibodies against
antibodies
Prior art date
Application number
MX2023000784A
Other languages
English (en)
Inventor
Surender Kharbanda
Donald W Kufe
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX2023000784A publication Critical patent/MX2023000784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación está dirigida a anticuerpos que se unen al dominio extracelular de MUC1- C (MUC1-C/ECD) y métodos para usar tales anticuerpos para tratar cánceres que expresan el antígeno MUC1.
MX2023000784A 2020-07-16 2021-07-15 Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). MX2023000784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (1)

Publication Number Publication Date
MX2023000784A true MX2023000784A (es) 2023-04-18

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000784A MX2023000784A (es) 2020-07-16 2021-07-15 Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).

Country Status (11)

Country Link
US (1) US20230265208A1 (es)
EP (1) EP4182354A1 (es)
JP (1) JP2023534959A (es)
KR (1) KR20230116767A (es)
CN (1) CN117693530A (es)
AU (1) AU2021310499A1 (es)
BR (1) BR112023000728A2 (es)
CA (1) CA3186181A1 (es)
IL (1) IL299903A (es)
MX (1) MX2023000784A (es)
WO (1) WO2022016190A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1791868B1 (en) * 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP2337801A4 (en) * 2008-10-06 2012-07-25 Minerva Biotechnologies Corp MUC1 ANTIBODIES *
JP6908381B2 (ja) * 2014-01-29 2021-07-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体

Also Published As

Publication number Publication date
WO2022016190A1 (en) 2022-01-20
KR20230116767A (ko) 2023-08-04
IL299903A (en) 2023-03-01
US20230265208A1 (en) 2023-08-24
CA3186181A1 (en) 2022-01-20
JP2023534959A (ja) 2023-08-15
AU2021310499A1 (en) 2023-03-09
CN117693530A (zh) 2024-03-12
BR112023000728A2 (pt) 2023-03-21
EP4182354A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
MX2016009954A (es) Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
EP4269594A3 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
TN2019000272A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
ZA202006859B (en) Antibodies specific for gucy2c and uses thereof
MX2017001599A (es) Anticuerpos novedosos y sus usos.
MX2021015495A (es) Composiciones y métodos para tratar cáncer.
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
CY1120326T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι για τη χρηση και την ταυτοποιηση τους
MX2022008214A (es) Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
ZA202008095B (en) Humanized antibodies against psma
MX2022004194A (es) Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos.
MX2023000784A (es) Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2022014224A (es) Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.
MX2020011614A (es) Anticuerpos con perfiles de glicanos modulados.
MX2020012788A (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso.
MX2021002077A (es) Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer.
CR20220523A (es) Anticuerpos anti-sea de muc1
WO2022251695A3 (en) Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)
MX2022004073A (es) Anticuerpo hibrido.